Rabbit Monoclonal CD7 Antibody

CD7 antibodies target the CD7 antigen, a cell surface glycoprotein belonging to the immunoglobulin superfamily. Predominantly expressed on T cells and natural killer (NK) cells, CD7 plays a role in cell-cell interactions, including T-cell activation and adhesion. Its function remains incompletely understood, but it is implicated in modulating signaling pathways involved in immune responses. CD7 antibodies have become critical tools in both research and clinical settings. In diagnostics, they are used to identify and characterize CD7-positive cells via flow cytometry, aiding in the classification of T-cell malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and certain lymphomas. Therapeutically, anti-CD7 antibodies are explored in immunotherapy, particularly for targeting CD7-expressing cancers. For instance, CD7-directed CAR-T cell therapies have shown promise in treating relapsed/refractory T-cell malignancies by redirecting immune cells to eliminate malignant cells. However, challenges persist due to CD7's expression on normal T cells, raising concerns about immunosuppression and on-target/off-tumor toxicity. Recent advancements include engineered antibodies with reduced immunogenicity and improved targeting specificity. Additionally, CD7 antibodies are studied in autoimmune diseases and transplantation for immune modulation. Structurally, CD7’s extracellular domain contains two Ig-like domains, facilitating antibody binding. Ongoing research aims to unravel its precise biological roles and optimize therapeutic applications while mitigating adverse effects.